Exact Sciences Corporation (NASDAQ:EXAS) pre-announced Q4 revenue of $472–475 million, beating the consensus estimate of $441.6 million, with upside in each of the company's operating segments.

While being pleased with a rebound in the core Cologuard screening business following disappointing Q3 results, analysts at Oppenheimer said they are cautious of screening outlook for Q1/22. Given a 4-week lag between ordering and test completion, the analysts expect the full weight of disruption from the Omicron surge to be recognized in Q1/22. As a result, the analysts don’t expect screening business to return to stable growth until Q2/22 at the earliest.